Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and adolescents between the ages of 12 and 17 years old. The bivalent version of its mRNA vaccine is designed to target both the original strain of SARS-CoV-2 and the BA.4/.5 omicron subvariants. Moderna also announced the completion of its EUA submission for the 6-to-11 age group.
 

Related News Articles

Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…
Headline
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral…
News
To enjoy a healthy Thanksgiving with family and friends, get vaccinated against the flu and COVID-19. That’s the message of AHA’s latest United Against the Flu…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response recently awarded over $500 million to prepare for clinical…